Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Bicara Therapeutics (NASDAQ:BCAX) to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports.

BCAX has been the subject of a number of other research reports. Morgan Stanley assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective for the company. Stifel Nicolaus began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target for the company. Cantor Fitzgerald assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating on the stock. TD Cowen started coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday. They set a “buy” rating and a $48.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Bicara Therapeutics presently has a consensus rating of “Buy” and an average target price of $43.33.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $23.82 on Tuesday. Bicara Therapeutics has a 12-month low of $18.33 and a 12-month high of $28.09.

Insiders Place Their Bets

In other news, major shareholder James E. Flynn bought 70,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the acquisition, the insider now directly owns 897,587 shares of the company’s stock, valued at $16,156,566. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Bicara Therapeutics news, major shareholder James E. Flynn bought 70,000 shares of the stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the acquisition, the insider now directly owns 897,587 shares of the company’s stock, valued at $16,156,566. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the transaction, the director now owns 4,303,418 shares in the company, valued at approximately $77,461,524. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Trading of Bicara Therapeutics

A hedge fund recently bought a new stake in Bicara Therapeutics stock. First Turn Management LLC acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 562,391 shares of the company’s stock, valued at approximately $14,324,000. Bicara Therapeutics comprises 2.3% of First Turn Management LLC’s holdings, making the stock its 24th largest position. First Turn Management LLC owned approximately 1.09% of Bicara Therapeutics as of its most recent filing with the Securities & Exchange Commission.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.